Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Human Papillomavirus | Research article

MiRNA detection in cervical exfoliated cells for missed high-grade lesions in women with LSIL/CIN1 diagnosis after colposcopy-guided biopsy

Authors: Jing Ye, Xiao-dong Cheng, Bei Cheng, Yi-fan Cheng, Xiao-Jing Chen, Wei-guo Lu

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Low-grade squamous intraepithelial lesion/cervical intraepithelial neoplasia grade 1 (LSIL/CIN1) preceded by colposcopy guided biopsy is recommended conservative follow-up, although some of these lesions are actually high-grade lesions, which are missed on an initial colposcopy. Therefore, in this work, we evaluate the potential role of miRNA detection in cervical exfoliated cells in a clinic-based population for predicting missed high-grade lesions in women diagnosed with LSIL/CIN1 after colposcopy-guided biopsy.

Methods

A total number of 177 women with a diagnosis of LSIL/CIN1 obtained by colposcopy-guided biopsy were grouped into two categories according to the histology of the conization specimens: consistent LSIL/CIN1 group (surgical pathology consistent with colposcopic diagnosis) and missed high-grade lesion group (surgical pathology found high-grade lesion). The expression of eight miRNAs, such as miRNA195, miRNA424, miRNA375, miRNA218, miRNA34a, miRNA29a, miRNA16–2, and miRNA20a was detected by real time-quantitative polymerase chain reaction (RT-qPCR) in cervical exfoliated cells of the 177 patients. Pearson Chi-Square was used to compare the performance efficiency of patients’ characteristics. Nonparametric Man-Whitney U test was used to assess differences in miRNA expression. The receiver operating characteristic (ROC) curve was used to assess the performance of miRNA evaluation in detecting missed high-grade lesions.

Results

Among the 177 women with biopsy-confirmed CIN1, 15.3% (27/177) had CIN2+ in the conization specimen (missed high-grade lesion group) and 84.7% (150/177) had CIN1-(consistent LSIL/CIN1 group). The relative expression of miRNA-195 and miRNA-29a in the missed high-grade lesion group was significantly lower than that in the consistent LSIL/CIN1 group. The relative expression of miRNA16–2 and miRNA20a in the missed high-grade lesion group was significantly higher than that in the consistent LSIL/CIN1 group. No significant difference was observed between these two groups regarding the other four miRNAs. Of these significant miRNAs, miRNA29a detection achieved the highest Youden index (0.733), sensitivity (92.6%), positive predictive value (46.2%), negative predictive value (98.3%) and higher specificity (80.7%) when identifying missed high-grade lesions.

Conclusions

Detection of miRNA might provide a new triage for identifying a group at higher risk of missed high-grade lesions in women with colposcopy diagnosis of LSIL/CIN1.
Appendix
Available only for authorised users
Literature
1.
Board Adult Treatment Editorial. Cervical Cancer treatment (PDQ). 2017.
2.
Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4): iv72-iv83.
3.
Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103:368–83.CrossRef
4.
Castle PE, Gage JC, Wheeler CM, Schiffman M. The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy. Obstet Gynecol. 2011;118(6):1222–9.CrossRef
5.
Sorbye SW, Arbyn M, Fismen S, Gutteberg TJ, Mortensen ES. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy. PLoS One. 2011;6(10):e26022.CrossRef
6.
Tverelv LR, Sørbye SW, Skjeldestad FE. Risk for cervical intraepithelial neoplasia grade 3 or higher in follow-up of women with a negative cervical biopsy. J Low Genit Tract Dis. 2018;22(3):201–6.CrossRef
7.
Katki HA, Gage JC, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Kinney WK. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S69–77.CrossRef
8.
Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. Benchmarking CIN 3+ risk as the basis for incorporating HPV and pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S28–35.CrossRef
9.
Schiffman M, Doorbar J, Wentzensen N, de Sanjosé S, Fakhry C, Monk BJ, Stanley MA, Franceschi S. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086.CrossRef
10.
Giorgi Rossi P, Carozzi F. Cervical cancer: screening and prevention. Ecyclopedy of cancer: Elsevier; 2018.
11.
Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Di. 2013;17:S1–S27.CrossRef
12.
Partridge EE, Abu-Rustum NR, Campos SM, Fahey PJ, Farmer M, Garcia RL, Giuliano A, Jones HW, Lele SM, Lieberman RW, Massad SL, Morgan MA, Reynolds RK, Rhodes HE, Singh DK, Smith-McCune K, Teng N, Trimbl CL, Valea F, Wilczynski S, Massad SL. Cervical cancer screening. National comprehensive cancer networks. J Natl Compr Cancer Netw. 2010;8(12):1358–86.CrossRef
13.
Gage JC, Hanson VW, Abbey K, Dippery S, Gardner S, Kubota J, Mark S, Jeronimo SD. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol. 2006;108:264–72.CrossRef
14.
Massad LS, Jeronimo J, Katki HA, Schiffman M. National Institutes of Health/American Society for Colposcopy and Cervical Pathology Research Group. The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia. J Low Genit Tract Dis. 2009;13(3):137–44.CrossRef
15.
Pretorius RG, Belinson JL, Burchette RJ, Hu S, Zhang X, Qiao YL. Regardless of skill, performing more biopsies increases the sensitivity of colposcopy. J Low Genit Tract Dis. 2011;15(3):180–8.CrossRef
16.
Zuchna C, Hager M, Tringler B, Georgoulopoulos A, Ciresa-Koenig A, Volgger B, Widschwendter A, Staudach A. Diagnostic accuracy of guided cervical biopsies: a prospective multicenter study comparing the histopathology of simultaneous biopsy and cone specimen. Am J Obstet Gynecol. 2010; 203(4): 321.e1–6.
17.
Bifulco G, De Rosa N, Lavitola G, Piccoli R, Bertrando A, Natella V, Carlo CD, Nappi LI. A prospective randomized study on limits of colposcopy and histology: the skill of colposcopist and colposcopy-guided biopsy in diagnosis of cervical intraepithelial lesions. Infect Agents Canc. 2015;10(1):47.CrossRef
18.
Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, Wang Y. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009;24:652–7.CrossRef
19.
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–70.CrossRef
20.
Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y. Reduced expression of thelet-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64:3753–6.CrossRef
21.
Michael MZ, O’Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1:882–91.PubMed
22.
Long MJ, Wu FX, Li P, Liu M, Li X, Tang H. MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. Cancer Lett. 2012;324:186–96.CrossRef
23.
Yao Q, Xu H, Zhang QQ, Zhou H, Qu LH. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem Biophys Res Commun. 2009;388:539–42.CrossRef
24.
Xu XM, Wang XB, Chen MM, Liu T, Li YX, Jia WH, Liu M, Li X, Tang H. MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. Cancer Lett. 2012;322:148–58.CrossRef
25.
Tian RQ, Wang XH, Hou LJ, Jia WH, Yang Q, Li YX, Liu M, Li X, Tang H. MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis. J Biol Chem. 2011;286:25556–63.CrossRef
26.
Peng RQ, Wan HY, Li HF, Liu M, Li X, Tang H. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-alpha- D -galactosamine: polypeptide N-acetylgalactosaminyltransferase 7. J Biol Chem. 2012;287:14301–9.CrossRef
27.
YuJ, Wang Y, Dong R, HuangX, Ding S, Qiu H. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J Cancer Res Clin Oncol. 2012; 138: 671–674.
28.
Wang F, Li Y, Zhou J, Xu J, Peng C, Ye F, Shen YM, Lu WG, Wan XY, Xie X. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol. 2011a;179(5):2580–8.CrossRef
29.
Xu J, Li Y, Wang F, Wang X, Cheng B, Ye F, Xie X, Zhou C, Lu W. Suppressed miR-424 expression via up regulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene. 2013;32(8):976–87.CrossRef
30.
Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene. 2008;27(18):2575–82.CrossRef
31.
Li B, Hu Y, Ye F, Li Y, Lv W, Xie X. Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. Int J Gynecol Canc. 2010;20(4):597–604.CrossRef
32.
Wang X, Meyers C, Guo M, Zheng ZM. Upregulation of p18Ink4c expression by oncogenic HPV E6 via p53-miR-34a pathway. Int J Canc. 2011b;129(6):1362–72.CrossRef
33.
Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ. Circulating microRNAs, potential biomarkers for drug-induced liver injury. P Natl Acad Sci. 2009;106(11):4402–7.CrossRef
34.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, Kathy C, O'Briant KC, April AA, Daniel W, Lin DW, Nicole UN, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Daniel B. Martin, Lin, DW. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8.CrossRef
35.
Puerta-Gil P, García-Baquero R, Jia AY, Ocaña S, Alvarez-Múgica M, Alvarez-Ossorio JL, Sánchez-Carbayo M. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder Cancer. Am J Pathol. 2012;180(5):1808–15.CrossRef
36.
Cui L, Zhang X, Ye G, Zheng T, Song H, Deng H, Xiao BX, Xia T, Yu XC, Le YP, Guo J. Gastric juice MicroRNAs as potential biomarkers for the screening of gastric Cancer. Cancer. 2013;119(9):1618–26.CrossRef
37.
Solomon D, Davey D, Kurman R, Moriarty A, O'connor D, Prey M, Stephen Raab S, Mark Sherman M, David Wilbur D, Thomas Wright T, Young N. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114–9.CrossRef
38.
Ye J, Cheng X, Chen X, et al. Prevalence and risk profile of cervical human papillomavirus infection in Zhejiang Province, Southeast China: a population-based study. Virol J. 2010a;7:66.CrossRef
39.
Ye J, Cheng X, Chen X, Ye F, Lu W, Xie X. Short-term type-specific HPV persistence and its predictors in an asymptomatic general female population in Zhejiang. China Int J Gynecol Obstet. 2010b;110(3):217–22.CrossRef
40.
Waxman AG, Chelmow D, Darragh TM, et al. Revised terminology for cervical histopathology and its implications for management of high-grade squamous intraepithelial lesions of the cervix. Obstet Gynecol. 2012;120(6):1465.CrossRef
41.
Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J, Lu WG, Wan XY, Ma D, Xie X. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J Pathol. 2011;224(4):484–95.CrossRef
42.
Schisterman EF, Perkins NJ, Liu A, et al. Optimal cut-point and its corresponding youden index to discriminate individuals using pooled blood samples. Epidemiology. 2005;16(1):73–81.CrossRef
43.
Mustafa RA, Santesso N, Khatib R, Mustafa AA, Wiercioch W, Kehar R, Shreyas GS, Chen YL, Cheung A, Hopkins J, Ma B, Lloyd N, Wu D, Broutet N, Ma B. Systematic reviews and meta-analyses of the accuracy of HPVtests, visual inspection with acetic acid, cytology, and colposcopy. Int J Gynaecol Obstet. 2016;132(03):259–65.CrossRef
44.
Boonlikit S, Asavapiriyanont S, Junghuttakarnsatit P, Tuipae S, Supakarapongkul W. Correlation between colposcopically directed biopsyand largeloop excision of the transformation zone and influence of age on the outcome. J Med Assoc Thail. 2006;89(03):299–305.
45.
Sideri M, Garutti P, Costa S, Cristiani P, Schincaglia P, Sassoli de Bianchi P, Naldoni C, Bucchi L. Accuracy of colposcopically directed biopsy: results from an online quality assurance programme for colposcopy in a population-based cervical screening setting in Italy. BioMed Res In 2015: 614035.
46.
Stoler MH, Schiffman M. Atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study (ALTS) group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL triage study. JAMA. 2001;285(11):1500–5.CrossRef
47.
Gage JC, Schiffman M, Hunt WC. New Mexico HPV Pap registry steering committee. Cervical histopathology variability among laboratories: a population-based statewide investigation. Am J Clin Pathol 2013; 139(03): 330–335.
48.
Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89:101–5.CrossRef
49.
González A, Colin D, Franceschi S, Goodill A, Green J, Peto J, Skegg D. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118:1481–95.CrossRef
50.
González A, Colin D, Franceschi S, Goodill A. GreenJ, Peto J. Skegg D Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study Int J Cancer. 2004;111:431–9.
51.
Pacchiarotti A, Ferrari F, Bellardini P, et al. Prognostic value of p16-INK4A protein in women with negative or CIN1 histology result: a follow-up study. Int J Cancer. 2014;134(4):897–904.CrossRef
52.
Rossi PG, Benevolo M, Vocaturo A, et al. Prognostic value of HPV E6/E7 mRNA assay in women with negative colposcopy or CIN1 histology result: a follow-up study. PLoS One. 2013;8(2):e57600.CrossRef
53.
Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi) genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014;14(6):395.CrossRef
54.
Boers A, Wang R, van Leeuwen RW, Klip HG, de Bock GH, Hollema HW, Criekinge WV, Meyer T, Denil S, van der Zee AGJ, Wisman GBA. Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3. Clin Epigenetics. 2016;8(1):29.CrossRef
55.
Balacescu O, Balacescu L, Baldasici O, Tudoran O, Achimas-Cadariu P. The role of miRNAs in diagnosis. InTech: Prognosis and Treatment Prediction in Cervical Cancer//Colposcopy and Cervical Pathology; 2017.
56.
Li J, Wan X, Qiang W, Li T, Huang W, Huang S, Wu D, Li Y. MiR-29a suppresses prostate cell proliferation and induces apoptosis via KDM5B protein regulation. Int J Clin Exp Med. 2015;8:5329–39.PubMedPubMedCentral
57.
Trehoux S, Lahdaoui F, Delpu Y, Renaud F, Leteurtre E, Torrisani J, Jonckheere N, Van Seuningen I. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochim Biophys Acta. 1853;2015:2392–403.
58.
Han HS, Son SM, Yun J, Jo YN, Lee OJ. MicroRNA-29a suppresses the growth, migration, and invasion of lung adenocarcinoma cells by targeting carcinoembryonic antigen-related cell adhesion molecule 6. FEBS Lett. 2014;588:3744–50.CrossRef
59.
Pereira PM, Marques JP, Soares AR, Carreto L, Santos MA. MicroRNA expression variability in human cervical tissues. PLoS One. 2010;5:e11780.CrossRef
60.
Yamamoto N, Kinoshita T, Nohata N, Yoshino H, Itesako T, Fujimura L, Mitsuhashi A, Usui H, Enokida H, Nakagawa M, Shozu M. Tumor-suppressive microRNA-29a inhibits cancer cell migration and invasion via targeting HSP47 in cervical squamous cell carcinoma. Int J Radiat Oncol. 2013;43(6):1855–63.
61.
Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113:18–25.CrossRef
62.
Schlecht NF, Platt RW, Duarte-Franco E, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst. 2003;95:1336–43.CrossRef
Metadata
Title
MiRNA detection in cervical exfoliated cells for missed high-grade lesions in women with LSIL/CIN1 diagnosis after colposcopy-guided biopsy
Authors
Jing Ye
Xiao-dong Cheng
Bei Cheng
Yi-fan Cheng
Xiao-Jing Chen
Wei-guo Lu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5311-3

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Study protocol

Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung Cancer patients: protocol for a prospective observational study

Research article

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

Research article

Adherence to quality breast cancer survivorship care in four Canadian provinces: a CanIMPACT retrospective cohort study

Research article

Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers

Study protocol

Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol

Research article

Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits